Sigfox and INDIGO® weel Join Forces to Promote 100% Connected Urban Mobility
12.7.2019 14:47:00 EEST | Business Wire | Press release
Self-service bicycle fleet INDIGO® weel, a subsidiary of the INDIGO group, has been fitted with sensors, supported by Sigfox's 0G network, that can accurately pinpoint their location at any given time. As the number of shared vehicles in circulation increases, this integration of Sigfox technology will help to better protect the fleet from damage or theft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190712005234/en/
Photo : INDIGO weel
The Sigfox solution offers multiple benefits for INDIGO® weel:
- An easier customer journey: pinpointing the location of bicycles more accurately, in real-time, allows users of the service to locate bikes on the street faster and more easily;
- Better protection against damage and theft due to a greater understanding of high-risk areas;
- A reduction in repair costs thanks to reusable sensors that can easily be transferred from a damaged bike to a new one;
- Flexible technology that can be used in other markets, if the INDIGO® weel service expands internationally, courtesy of Sigfox's global 0G network that spans some sixty countries;
- Durable sensors that consume very little energy
Together, INDIGO® weel and Sigfox are providing a solution to the public that addresses a number of the current challenges facing mobility services. Population growth in cities, as well as increasing environmental awareness now requires us to reconsider the way we move around each day. Innovative private sector services are therefore needed, in order to be able to offer a wider range of mobility solutions to the public. These must, however, complement the existing public transport offering, with those in charge working closely with city authorities in metropolitan areas.
New mobility solutions have been changing the face of city centre travel in recent years, but in order to be fully effective, they still have to find their place in the landscape. In this new market, INDIGO® weel is positioning itself as an innovative brand, keen to constantly evolve and partner with other forward-thinking businesses to do that.
One example of this innovation prompts users to take a photo at the end of their bike rental period to certify that the vehicle is in good parking condition. Each photo is then processed by customer services and users who comply with national, local and ‘Our Service’ rules will gain access to more advantageous offers.
Any change involves some risks and challenges, but the association between Sigfox and INDIGO® weel is already reaping benefits. Since the fleet was equipped with connected sensors, improvements to the geolocation system has reduced bicycle damage by a factor of 4. In addition, bicycle repair/replacement is now also faster than in the past. These improvements benefit INDIGO® weel, but also, more broadly, the inhabitants of cities where the connected vehicles are available, providing them with a high quality, sustainable service.
Jean Gadrat, CEO of INDIGO® weel, explains: "Public stakeholders and users today want a wider range of mobility solutions at their disposal and innovation in the sector that will help shape the city of tomorrow. It is in this context that we enter the market as a private company, in order to provide citizens with a respectful, complementary offering. INDIGO® weel wants to be a responsible player in the urban mobility market. We work tirelessly to offer the best possible service to our customers and make our products more efficient, which is why we have chosen to embed Sigfox’s technology into the fleet. It allows us to strengthen the sustainability of our offering and fully integrate our vehicles into the urban ecosystem.”
Patrick Cason, General Manager at Sigfox France, said: "Through this collaboration, we are once again demonstrating the many ways in which our 0G network can be used to serve society. The challenges of mobility, especially in cities, are many and well known. Faced with increasingly populated cities and an environmental awareness that can no longer be ignored, we must create new, more sustainable mobility solutions. Free floating bike is one of them. We are working with INDIGO® weel to provide the best service possible to meet the needs of citizens and to ensure that free floating bike finds its place in the city.”
About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.
Today, the network is available in 60 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190712005234/en/
Contact information
Press:
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
